Nanotechnology Now - Press Release: Nanostart-holding Lumiphore and Algeta Announce Further Expansion of Their Global Partnership

Home > Press > Nanostart-holding Lumiphore and Algeta Announce Further Expansion of Their Global Partnership

Abstract:
Nanostart-holding Lumiphore, Inc has announced that Algeta ASA, a company focused on the development of novel targeted cancer therapeutics, has exercised its option to take an exclusive worldwide licence to Lumiphore's patented Lumi4® bi-functional chelator technology and has extended the collaboration to include additional chelator families. The license enables the integration of Lumiphore's Lumi4® complexes into the targeted radiotherapeutics and companion diagnostics from Algeta.

Nanostart-holding Lumiphore and Algeta Announce Further Expansion of Their Global Partnership

Frankfurt, Germany and Richmond, CA | Posted on May 2nd, 2013

Lumiphore's Lumi4® technology is based on a unique class of bi-functional metal chelators that forms a cage structure surrounding a radioactive metal ion, which can then be covalently attached to a range of tumor-targeting molecules, such as monoclonal antibodies, to create cancer therapeutics. These bi-functional chelators provide a critical component enabling payload delivery for radio-therapeutic agents.

Algeta originally signed an option/license agreement with Lumiphore around this technology in 2010 and subsequently extended it to enable further evaluation to be conducted. This stage of evaluation has now been completed successfully.

In parallel with this license agreement, Algeta has also been granted a license by Lumiphore covering a second class of bi-functional chelators. Under the agreements, Algeta has the future potential to develop in vivo companion diagnostics for radio-imaging.

"Lumiphore's goal is to bring the benefits of bi-functional metal-chelation technology, through a variety of synthetic designs, to therapeutic markets that use targeted radiopharmaceuticals to treat cancer by the tumoricidal action of the radionuclide micro-irradiation. The ability to chelate radioactive metal isotopes (radiotracers) and covalently attach them to therapeutic antibodies, peptides, proteins, or other receptor targeting molecules will benefit targeted delivery to cancer sites and has the potential to make current therapeutic antibodies more effective," said Dr. Ken Raymond, President and CEO of Lumiphore.

"Our technology also offers another therapeutic modality for those using antibody-drug conjugates," explained Steve Blose, Lumiphore's Chief Business Officer. He further explained that pharmaceutical companies using therapeutic antibodies could incorporate Lumiphore's technology to develop site-directed in vivo radiodiagnostics to diagnose and monitor therapeutic efficacy through radio-imaging.

####

About Nanostart AG
Nanostart AG headquartered in the German financial capital of Frankfurt, is a leading nanotechnology investment company, with portfolio companies spanning the globe from Silicon Valley to Singapore. The company provides venture capital financing for nanotechnology companies in various growth phases with a focus on innovation-driven industries of the future such as cleantech, life sciences and IT/electronics. Through its holding in Singapore, Nanostart is proud to be the investment partner of the Singaporean government.

About Lumiphore:
Based in Richmond, California, Lumiphore Inc., a privately held company, is a biotechnology leader in the development of proprietary fluorescent-metal lanthanide technology for use in high-value applications, which are commercialized through market-specific alliances with corporate partners. Lumiphore has exclusive licenses to the basic science developed at the University of California, Berkeley in the laboratory of Professor Kenneth N. Raymond, a world expert on lanthanide chemistry. For more information about Lumiphore, visit www.lumiphore.com.

Disclaimer:
This notice constitutes neither an offer to sell nor a solicitation of offers to purchase or subscribe to securities. There will be no public offering of securities of Nanostart AG in conjunction with the existing listing of its shares in the “Entry Standard” segment of the regulated unofficial market (Freiverkehr) on the Frankfurt Stock Exchange. This notice does not constitute a securities prospectus. Neither this notice nor the information contained within is intended for direct or indirect distribution within Canada, Australia or Japan.

For more information, please click here

Contacts:
Nanostart AG
Dr. Hans Joachim Duerr
Head of Corporate Communications
Goethestrasse 26-28
D-60313 Frankfurt, Germany
phone: +49 (0)69-21 93 96 111
fax: +49 (0)69-21 93 96 150

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: